GlaxoSmithKline ($GSK) says it's rolling out sales and marketing reforms around the world. Apparently, the changes come none too soon. The British drugmaker opened another bribery investigation, this time in Iraq, to check out allegations that it paid government-employed physicians to promote its products.
And Glaxo hasn't yet finished working through the scandalous Chinese bribery allegations that kicked off an industrywide corruption crackdown.
So, CEO Andrew Witty and his team sound a bit ... conflicted. Read more from FiercePharmaMarketing >>